Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial
Clinical Pharmacology in Drug Development · Published 2026-08-01 · DOI 10.1002/cpdd.70087
Free full text
Authors (18)
Mita Kuchimanchi, Trine Lembrecht Jørgensen, Eva Hanze, Angela Jain, Oskar Alskär, Oleksandr Zub, Mark S. Shahin, Anthoula Koliadi, Bhavana Pothuri, Thomas Krivak, Mikalai Pishchyk, Yakir Segev, Floor J. Backes, Christine Gennigens, Sara Bouberhan, Stefan Zajic, Murad Melhem, Joseph Buscema
Abstract
PubPorta does not have an abstract for this article yet.
Read the article at the publisher →
Publication details
- Year
- 2026
Citation
Kuchimanchi, M., Jørgensen, T., Hanze, E., et al. (2026). Exposure–Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70087
Related articles
- Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers · Clinical Pharmacology in Drug Development · 2026 · Same journal
- Distributed Manufacturing, Foreign Establishments, and Why the FDA's New Proposed Rule Matters to Clinical Pharmacology · Clinical Pharmacology in Drug Development · 2026 · Same journal
- Pharmacokinetics, Bioequivalence, and Safety Evaluation of Two Voriconazole Tablets in Healthy Chinese Volunteers · Clinical Pharmacology in Drug Development · 2026 · Same journal
- Pharmacokinetics and Bioequivalence of Tamsulosin Hydrochloride Extended‐Release Capsules in Healthy Chinese Volunteers: A Randomized, Open‐Label, Crossover Study Under Fasting and Fed Conditions · Clinical Pharmacology in Drug Development · 2026 · Same journal
- Pharmacokinetic Interaction Between Atorvastatin and Hybutimibe in Healthy Chinese Volunteers · Clinical Pharmacology in Drug Development · 2026 · Same journal
- Single‐Dose Pharmacokinetic Assessment of TNX‐102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open‐Label Studies in Healthy Volunteers · Clinical Pharmacology in Drug Development · 2026 · Same journal
- From Reflection to Acceleration: Clinical Pharmacology’s 2025 Lessons and 2026 Opportunities · Clinical Pharmacology in Drug Development · 2026 · Same journal
- Pharmacokinetic Comparability of ABP 654, a Biosimilar to Ustekinumab, Administered Either via Prefilled Syringe or Autoinjector in Healthy Adults: Results from a Randomized, Open‐Label, Parallel‐Group Study · Clinical Pharmacology in Drug Development · 2026 · Same journal
- Pharmacokinetics and Safety of VV116 in Subjects With Mild or Moderate Hepatic Impairment Compared With Healthy Controls: A Phase I, Open‐Label Study · Clinical Pharmacology in Drug Development · 2026 · Same journal
- A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers · Clinical Pharmacology in Drug Development · 2026 · Same journal